Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma

Cancer Immunology Research

Volumn 3, Issue 3, 2015, Pages 278-287

  Sabado, Rachel Lubong ^a,b   Pavlick, Anna ^a   Gnjatic, Sacha ^b,c   Cruz, Crystal M ^a   Vengco, Isabelita ^a   Hasan, Farah ^a   Spadaccia, Meredith ^a   Darvishian, Farbod ^d   Chiriboga, Luis ^d   Holman, Rose Marie ^a   Escalon, Juliet ^a   Muren, Caroline ^a   Escano, Crystal ^a   Yepes, Ethel ^a   Sharpe, Dunbar ^a   Vasilakos, John P ^e   Rolnitzsky, Linda ^a   Goldberg, Judith D ^a   Mandeli, John ^b   Adams, Sylvia ^a   Jungbluth, Achim ^d   Pan, Linda ^c   Venhaus, Ralph ^c   Ott, Patrick A ^a,f   Bhardwaj, Nina ^a,b,d   more..

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e 3M Drug Delivery Systems Division   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONTANIDE ISA 51; NY ESO 1 ANTIGEN; RESIQUIMOD; TOLL LIKE RECEPTOR 7; CANCER ANTIBODY; CANCER VACCINE; CTAG1B PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; MANNITOL; MEMBRANE PROTEIN; OLEIC ACID; PEPTIDE FRAGMENT; TUMOR ANTIGEN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DIZZINESS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EYE MELANOMA; FATIGUE; FEMALE; GRANULOMA; HEADACHE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE NECROSIS; INJECTION SITE REACTION; MALE; MELANOMA; MYALGIA; RASH; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN INDURATION; TOPICAL TREATMENT; URTICARIA; VOMITING; ANALOGS AND DERIVATIVES; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; IMMUNOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMIDAZOLES; IMMUNITY, CELLULAR; MALE; MANNITOL; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; OLEIC ACIDS; PEPTIDE FRAGMENTS; VACCINATION;

EID: 84962279040     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0202     Document Type: Article

References (46)

1. Nagata Y, Ono S, Matsuo M, Gnjatic S, Valmori D, Ritter G, et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci U S A 2002;99: 10629-34.
2. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patientswith clinical benefit. ProcNatl Acad Sci USA 2008;105:20410-5.
3. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511.
4. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95.
5. Kopp E, Medzhitov R. Recogntion of microbial infection by Toll-like receptors. Curr Opin Immunol 2003;15:396-401.
6. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004;5:508-15.
7. Wang RF Regulatory T cells and innate immune regulation in tumor immunity. Springer Semin Immunopathol 2006;28:17-23.
8. Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants? Cancer J 2010;16:382-91.
9. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy 2009;1:949-64.
10. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, et al. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013;2:e25238.
11. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008;181:776-84.
12. Vasilakos JP, Tomai MA. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev Vaccines 2013;12:809-19.
13. Ahonen CL, Gibson SJ, Smith RM, Pederson LK, Lindh JM, Tomai MA, et al. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell Immunol 1999;197:62-72.
14. Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999;191: 10-9.
15. Tel J, Sittig SP, Blom RA, Cruz LJ, Schreibelt G, Figdor CG, et al. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J Immunol 2013;191: 5005-12.
16. Kwissa M, Nakaya HI, Oluoch H, Pulendran B. Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 2012;119:2044-55.
17. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 2004;22: 1799-809.
18. Chang BA, Cross JL, Najar HM, Dutz JP. Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine 2009;27:5791-9.
19. Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 2013;121:251-9.
20. Meyer T, Surber C, French LE, Stockfleth E. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Investig Drugs 2013;22: 149-59.
21. Vaughan HA, Svobodova S, Macgregor D, Sturrock S, Jungbluth AA, Browning J, et al. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 2004;10:8396-404.
22. Gnjatic S, Ritter E, Buchler MW, Giese NA, Brors B, Frei C, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A 2010; 107:5088-93.
23. Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, O'Neill D, et al. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM) - correlation with prognostic factors. Cancer Immun 2007;7:11.
24. Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, et al. Phase Itrial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012;18:6497-508.
25. Dutoit V, Taub RN, Papadopoulos KP, Talbot S, Keohan ML, Brehm M, et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 2002;110: 1813-22.
26. Ebert LM, MacRaild SE, Zanker D, Davis ID, Cebon J, Chen W. A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS ONE 2012;7:e48424.
27. Francois V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K, et al. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res 2009;69:4335-45.
28. Kutikhin AG Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol 2011;72:1095-116.
29. Trejo-de la OA, Hernandez-Sancen P, Maldonado-Bernal C. Relevance of single-nucleotide polymorphisms in human TLR genes to infectious and inflammatory diseases and cancer. Genes Immun 2014;15:199-209.
30. Cervantes JL, Weinerman B, Basole C, Salazar JC. TLR8: the forgotten relative revindicated. Cell Mol Immunol 2012;9:434-8.
31. Davila S, Hibberd ML, Hari Dass R, Wong HE, Sahiratmadja E, Bonnard C, et al. Genetic association and expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis. PLoS Genet 2008;4:e1000218.
32. Wang CM, Chang SW, Wu YJ, Lin JC, Ho HH, Chou TC, et al. Genetic variations in Toll-like receptors (TLRs 3/7/8) are associated with systemic lupus erythematosus in a Taiwanese population. Sci Rep 2014;4:3792.
33. Oh DY, Baumann K, Hamouda O, Eckert JK, Neumann K, Kücherer C, et al. A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. AIDS 2009;23:297-307.
34. Monroy CM, Cortes AC, Lopez MS, D'Amelio AM Jr, Etzel CJ, Younes A, et al. Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes. Mol Carcinog 2011;50:36-46.
35. + T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res 2013;1:340-50.
36. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 2007;104:8947-52.
37. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189:371-80.
38. Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014; 6:232ra51.
39. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 2005;5:617-28.
40. Alvarez D, Vollmann EH, von Andrian UH Mechanisms and consequences of dendritic cell migration. Immunity 2008;29:325-42.
41. + nonlymphoid dendritic cells. Immunity 2012;37: 60-73.
42. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004;101:10697-702.
43. + helper T cell responses in cancer patients. Blood 2005;106:1008-11.
44. +T cells following peptide vaccination. J Immunol 2006;176:6340-6.
45. Moller-Larsen S, Nyegaard M, Haagerup A, Vestbo J, Kruse TA, Borglum AD. Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders. Thorax 2008;63:1064-9.
46. + T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 2011;108:16723-8.